News articles about Nevro (NYSE:NVRO) have trended somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Nevro earned a news sentiment score of 0.17 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 45.8953239475296 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Nevro stock opened at $86.52 on Friday. Nevro has a 52 week low of $65.00 and a 52 week high of $97.70. The company has a debt-to-equity ratio of 0.58, a quick ratio of 5.91 and a current ratio of 7.61. The stock has a market capitalization of $2,615.81, a P/E ratio of -69.22 and a beta of -0.53.
Nevro (NYSE:NVRO) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01). Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The business had revenue of $97.96 million during the quarter, compared to analysts’ expectations of $96.87 million. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. Nevro’s quarterly revenue was up 38.9% on a year-over-year basis. analysts forecast that Nevro will post -0.76 EPS for the current fiscal year.
NVRO has been the topic of a number of recent analyst reports. BMO Capital Markets reaffirmed a “buy” rating and set a $100.00 price target on shares of Nevro in a research note on Thursday, December 14th. ValuEngine cut shares of Nevro from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research cut shares of Nevro from a “hold” rating to a “sell” rating in a research note on Wednesday, February 28th. Finally, Goldman Sachs initiated coverage on shares of Nevro in a research note on Wednesday. They set a “neutral” rating and a $83.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $97.44.
In related news, Director Wilfred E. Jaeger sold 160,542 shares of the business’s stock in a transaction dated Wednesday, March 7th. The shares were sold at an average price of $80.77, for a total value of $12,966,977.34. Following the sale, the director now directly owns 1,518 shares in the company, valued at approximately $122,608.86. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Wilfred E. Jaeger sold 14,458 shares of the business’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total transaction of $1,204,062.24. Following the completion of the sale, the director now owns 1,518 shares in the company, valued at $126,419.04. The disclosure for this sale can be found here. Insiders sold a total of 234,116 shares of company stock worth $18,913,822 over the last quarter. Insiders own 12.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Nevro (NVRO) Getting Somewhat Favorable News Coverage, Accern Reports” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/nevro-nvro-getting-somewhat-favorable-news-coverage-accern-reports.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.